Barratt Developments PLC (the Group ) is issuing a trading update in respect of the half year ended 31 December 2020 (the period ) ahead of publication of its interim results on 4 February 2021.
David Thomas, Chief Executive commented: Throughout the pandemic, our teams have worked hard to make our operations COVID-secure and our first priority continues to be keeping our employees, sub-contractors, suppliers and customers safe. I d like to thank our people for their efforts in helping us to rebuild completion volumes, drive further operational improvements and deliver on our commitment to build the highest quality homes across the country. Despite the ongoing challenges presented by the pandemic, we are confident that our operating performance and strong financial position provide us with the resilience and flexibility to respond to the operating environment in FY21 and beyond.
Vanguard News
NIMC resumes NIN enrolment nationwide
On
By Emmanuel Elebeke
The National Identity Management Commission (NIMC) says it has resumed normal enrolment services for the National Identity Number (NIN) at its centres nationwide.
This followed the suspension of its two-day strike action by the staff of the Commission which commenced on Wednesday.
According to a statement from the Commission, signed by the Head of Corporate Communications, Mr. Kayode Adegoke, all the glitches experienced since January 6, 2021, had been sorted out before the resumption of the enrolment exercise by the striking staff.
READ ALSO:
Recall that the enrolment services at NIMC centres were temporarily disrupted when the local chapter of the Association of Senior Civil Servants of Nigeria (ASCSN) of NIMC embarked on industrial action on Wednesday, January 6, 2021, immediately after their congress.
Median Technologies: Disclosure of total number of voting rights and number of shares in the capital as of December 31st, 2020
Regulatory News:
(excluding treasury shares )
(including treasury shares )
( ) pursuant to article 223-11 of the AMF s General Regulations
About Median Technologies:
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to